Literature DB >> 6451468

Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil.

Y Ohta, K Sueki, K Kitta, K Takemoto, H Ishitsuka, Y Yagi.   

Abstract

The immunosuppressive effect of 5'-deoxy-5-fluorouridine (5'-DFUR, Ro 21-9738) was examined for both humoral and cell-mediated immunity in mice in comparison with that of 5-fluorouracil and Ftorafur (FT-207). By both oral and intraperitoneal administration, 5'-DFUR was found to be much less suppressive than 5-fluorouracil and FT-207 in all immune responses tested; hemolysin plaque-forming cells, serum hemolysin titer, delayed-type hypersensitivity and allogeneic tumor rejection. Furthermore, 5'-DFUR did not induce any reduction in either the spleen weight, thymus weight, total spleen cell number, or peripheral leucocyte number.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6451468

Source DB:  PubMed          Journal:  Gan        ISSN： 0016-450X


  14 in total

1.  Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.

Authors:  M Iigo; M Miwa; H Ishitsuka; K Nitta
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Immunomodulating activity of thymosin fraction 5 and thymosin alpha 1 in immunosuppressed mice.

Authors:  Y Ohta; K Sueki; Y Yoneyama; E Tezuka; Y Yagi
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 3.  Capecitabine: preclinical pharmacology studies.

Authors:  H Ishitsuka
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

4.  Prevention of indigenous infection of mice with Escherichia coli by nonspecific immunostimulation.

Authors:  K Nomoto; T Yokokura; M Mitsuyama; Y Yoshikai; K Nomoto
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

5.  Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.

Authors:  H Eda; K Fujimoto; S Watanabe; M Ura; A Hino; Y Tanaka; K Wada; H Ishitsuka
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  New approach to metabolism of 5'-deoxy-5-fluorouridine in humans with fluorine-19 NMR.

Authors:  M C Malet-Martino; R Martino; A Lopez; J P Béteille; M Bon; J Bernadou; J P Armand
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.

Authors:  L M Weiner; G R Hudes; J Kitson; J Walczak; P Watts; S Litwin; P J O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Recovery of humoral and cellular immunity by soluble mediators after 5-fluorouracil-induced immunosuppression.

Authors:  V J Merluzzi; K Last-Barney; B M Susskind; R B Faanes
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

9.  5'-Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice.

Authors:  H Eda; Y Tanaka; H Ishitsuka
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer.

Authors:  M Yoshimoto; K Tada; N Tokudome; G Kutomi; M Tanabe; T Goto; S Nishimura; M Makita; F Kasumi
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.